# Chimera Clinical Advisory Board Charter (Enhanced Version)

<div align="center">
<img src="https://img.shields.io/badge/-%F0%9F%A7%A0%20CHIMERA%20CLINICAL%20ADVISORY%20BOARD%20%F0%9F%A6%BE-6236FF?style=for-the-badge&labelColor=1A1A2E" alt="Chimera Clinical Advisory Board"/>

**Guiding the Future of Brain-Controlled Exoskeleton Technology**

*Version 2.0 | Effective Date: April 2025*

[![FDA Compliance](https://img.shields.io/badge/FDA-Compliance%20Ready-green?style=flat-square&logo=data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgMCAyNCAyNCI+PHBhdGggZD0iTTEyIDJDNi41IDIgMiA2LjUgMiAxMnM0LjUgMTAgMTAgMTAgMTAtNC41IDEwLTEwUzE3LjUgMiAxMiAyem0tMSAxNkg3di0yaDR2MnptNi40LTRINi42Yy0uOSAwLTEuNi0uNy0xLjYtMS42VjYuNkM1IDUuNyA1LjcgNSA2LjYgNWgxMC44Yy45IDAgMS42LjcgMS42IDEuNnY1LjhjMCAuOS0uNyAxLjYtMS42IDEuNnoiIGZpbGw9IndoaXRlIi8+PC9zdmc+)](https://www.fda.gov/medical-devices/digital-health-center-excellence/software-medical-device-samd)
[![ISO 14155](https://img.shields.io/badge/ISO%2014155-Clinical%20Investigation-blue?style=flat-square)](https://www.iso.org/standard/71690.html)
[![21 CFR Part 11](https://img.shields.io/badge/21%20CFR%20Part%2011-Compliant-blue?style=flat-square)](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=11)
</div>

## 1. Executive Summary

The Chimera Clinical Advisory Board (CAB) is a cornerstone of our regulatory and clinical strategy, providing expert guidance for the development, validation, and market introduction of the Chimera brain-computer interface (BCI) controlled exoskeleton platform. This charter establishes a world-class advisory body comprising leading experts in neurology, rehabilitation medicine, neuroscience, bioethics, patient advocacy, regulatory affairs, and clinical research methodology.

The CAB will play a critical role in ensuring that the Chimera platform meets the highest standards of clinical efficacy, safety, and ethical implementation while navigating the complex regulatory landscape for novel neurotechnology devices. Through strategic guidance on clinical trial design, regulatory pathways, safety monitoring, and technology assessment, the CAB will accelerate our path to market while maximizing clinical impact and commercial success.

This charter defines the CAB's purpose, responsibilities, membership requirements, operational procedures, and governance structure, establishing a framework for leveraging expert insights to achieve our billion-dollar market potential.

## 2. Purpose and Scope

### 2.1 Mission Statement

The Chimera Clinical Advisory Board exists to ensure that our brain-controlled exoskeleton technology achieves optimal clinical outcomes, maintains the highest safety standards, and navigates regulatory pathways efficiently while addressing ethical considerations in neurotechnology implementation.

### 2.2 Strategic Objectives

The CAB will support Chimera in achieving the following strategic objectives:

1. **Accelerate Regulatory Approval**: Provide expert guidance to optimize regulatory strategy and expedite FDA clearance/approval
2. **Enhance Clinical Validation**: Design and oversee robust clinical studies that demonstrate safety and effectiveness
3. **Maximize Therapeutic Impact**: Identify optimal patient populations and clinical protocols to maximize therapeutic benefits
4. **Ensure Ethical Implementation**: Address neuroethical considerations and establish responsible use guidelines
5. **Support Market Adoption**: Develop strategies for clinical integration and reimbursement pathways
6. **Maintain Competitive Advantage**: Provide insights on emerging technologies and competitive positioning

### 2.3 Scope of Authority

The CAB serves in an advisory capacity to Chimera leadership with the following scope:

- Provides recommendations on clinical and regulatory strategy
- Reviews and advises on clinical study designs and protocols
- Evaluates safety data and recommends risk mitigation strategies
- Offers guidance on ethical considerations and responsible implementation
- Does not have direct decision-making authority over company operations
- Cannot commit company resources without executive approval

## 3. Responsibilities

### 3.1 Clinical Strategy Development

#### 3.1.1 Clinical Trial Design and Oversight
- Develop comprehensive clinical development plan aligned with regulatory requirements
- Design statistically rigorous clinical trial protocols with appropriate endpoints
- Recommend inclusion/exclusion criteria to optimize patient selection
- Advise on site selection and investigator qualifications
- Review clinical study progress and interim results
- Recommend protocol modifications based on emerging data

#### 3.1.2 Outcome Measures and Endpoints
- Identify clinically meaningful primary and secondary endpoints
- Recommend validated assessment tools and measurement techniques
- Advise on patient-reported outcome measures
- Develop strategies for long-term efficacy monitoring
- Guide development of novel outcome measures specific to BCI-controlled exoskeletons

#### 3.1.3 Therapeutic Protocol Development
- Design optimal protocols for device calibration and patient training
- Establish guidelines for therapy progression and intensity
- Develop protocols for home use vs. clinical setting use
- Create standards for therapist training and certification
- Recommend approaches for personalizing therapy to individual patients

### 3.2 Regulatory Guidance

#### 3.2.1 Regulatory Strategy
- Advise on optimal regulatory pathways (510(k), De Novo, PMA)
- Guide preparation for pre-submission meetings with FDA
- Review regulatory submissions for clinical content accuracy
- Provide insights on international regulatory approaches (EU MDR, PMDA, etc.)
- Advise on post-market surveillance requirements

#### 3.2.2 Documentation Review
- Review clinical sections of regulatory submissions
- Evaluate clinical evidence summaries and clinical evaluation reports
- Assess benefit-risk analyses for regulatory purposes
- Review clinical validation protocols and reports
- Provide expert opinions for regulatory responses

#### 3.2.3 Compliance Oversight
- Ensure clinical studies comply with GCP requirements
- Advise on implementation of 21 CFR Part 11 for clinical data
- Guide compliance with human subject protection regulations
- Provide insights on evolving regulatory requirements for AI/ML in medical devices
- Advise on clinical aspects of quality system implementation

### 3.3 Safety and Ethics Oversight

#### 3.3.1 Safety Monitoring
- Establish safety monitoring protocols for clinical studies
- Review adverse event reports and recommend responses
- Develop risk mitigation strategies for identified safety concerns
- Advise on post-market surveillance methodologies
- Guide development of safety training materials for users

#### 3.3.2 Ethical Framework Development
- Establish ethical guidelines for BCI technology implementation
- Address privacy concerns related to neural data collection
- Develop protocols for informed consent in vulnerable populations
- Provide guidance on equitable access considerations
- Address potential psychological impacts of BCI technology

#### 3.3.3 Risk Management
- Review risk analysis documentation
- Advise on risk control implementation
- Evaluate residual risk acceptability
- Guide benefit-risk determinations
- Recommend approaches for communicating risks to users

### 3.4 Technology Assessment

#### 3.4.1 Clinical Utility Evaluation
- Assess technology performance in clinical settings
- Evaluate user experience from patient and clinician perspectives
- Identify opportunities for technology refinement
- Compare performance to standard of care and competitive technologies
- Recommend feature prioritization based on clinical impact

#### 3.4.2 Technical Performance Review
- Evaluate BCI signal acquisition and processing performance
- Assess exoskeleton mechanical performance and safety
- Review human factors and usability testing results
- Provide feedback on user interface design
- Evaluate algorithm performance and adaptation capabilities

#### 3.4.3 Innovation Guidance
- Identify unmet clinical needs for future development
- Recommend technology enhancements based on clinical experience
- Advise on integration with complementary technologies
- Guide development of next-generation features
- Provide insights on emerging competitive technologies

### 3.5 Knowledge Dissemination

#### 3.5.1 Publication Strategy
- Guide development of publication plan for clinical results
- Review key manuscripts prior to submission
- Recommend target journals and conferences
- Advise on addressing reviewer comments
- Support development of white papers and review articles

#### 3.5.2 Clinical Education
- Guide development of training materials for clinicians
- Advise on certification programs for clinical users
- Support creation of patient education materials
- Recommend approaches for clinical community engagement
- Provide guidance on medical education initiatives

#### 3.5.3 Stakeholder Engagement
- Facilitate connections with key opinion leaders
- Support engagement with patient advocacy organizations
- Advise on payer and health system education
- Guide development of value proposition messaging
- Support engagement with professional societies

## 4. Membership Composition

### 4.1 Expertise Requirements

The CAB consists of 7-9 members representing diverse expertise relevant to brain-controlled exoskeletons:

<table>
<tr>
<th>Expertise Area</th>
<th>Required Experience</th>
<th>Key Responsibilities</th>
<th>Number of Members</th>
</tr>
<tr>
<td><strong>Neurology</strong></td>
<td>
• Expertise in motor neuron diseases, spinal cord injury, or stroke rehabilitation<br>
• Experience with brain-computer interfaces in clinical settings<br>
• Board certification in neurology<br>
• Minimum 10 years clinical practice<br>
• Publication record in relevant areas
</td>
<td>
• Lead clinical protocol development<br>
• Evaluate neurological safety aspects<br>
• Guide patient selection criteria<br>
• Advise on neurological outcome measures<br>
• Support regulatory neurological assessments
</td>
<td align="center">1-2</td>
</tr>
<tr>
<td><strong>Physical Medicine and Rehabilitation</strong></td>
<td>
• Expertise in exoskeleton-assisted rehabilitation<br>
• Experience with mobility assistive technologies<br>
• Board certification in PM&R<br>
• Minimum 8 years clinical practice<br>
• Experience in rehabilitation technology implementation
</td>
<td>
• Guide rehabilitation protocol development<br>
• Advise on functional outcome measures<br>
• Evaluate usability in rehabilitation settings<br>
• Develop therapist training requirements<br>
• Support reimbursement strategy
</td>
<td align="center">1-2</td>
</tr>
<tr>
<td><strong>Neuroscience/Neurophysiology</strong></td>
<td>
• Expertise in EEG signal processing and interpretation<br>
• Understanding of motor control and neural plasticity<br>
• PhD in neuroscience or related field<br>
• Research experience with BCI technology<br>
• Publication record in neural signal processing
</td>
<td>
• Evaluate BCI algorithm performance<br>
• Guide signal processing improvements<br>
• Advise on neuroplasticity considerations<br>
• Support technical performance assessment<br>
• Guide development of novel BCI approaches
</td>
<td align="center">1</td>
</tr>
<tr>
<td><strong>Bioethics</strong></td>
<td>
• Expertise in neuroethics and emerging technologies<br>
• Experience with regulatory ethics committees<br>
• Formal training in bioethics<br>
• Publication record in neuroethics<br>
• Experience with IRB or ethics committees
</td>
<td>
• Develop ethical framework for technology use<br>
• Guide informed consent processes<br>
• Advise on privacy protections for neural data<br>
• Address equity and access considerations<br>
• Support responsible innovation practices
</td>
<td align="center">1</td>
</tr>
<tr>
<td><strong>Patient Advocacy</strong></td>
<td>
• Representative from relevant patient community<br>
• Experience in patient-centered research design<br>
• Connection to patient advocacy organizations<br>
• Understanding of lived experience with mobility impairment<br>
• Experience in patient advisory roles
</td>
<td>
• Ensure patient perspective in development<br>
• Guide development of patient-reported outcomes<br>
• Advise on user experience considerations<br>
• Support patient recruitment strategies<br>
• Facilitate connections with patient communities
</td>
<td align="center">1</td>
</tr>
<tr>
<td><strong>Regulatory Affairs</strong></td>
<td>
• Experience with FDA medical device approval processes<br>
• Knowledge of Software as a Medical Device (SaMD) regulations<br>
• RAC certification preferred<br>
• Minimum 8 years in regulatory affairs<br>
• Experience with Class II/III medical device submissions
</td>
<td>
• Guide regulatory strategy development<br>
• Advise on regulatory submission content<br>
• Support preparation for FDA meetings<br>
• Provide insights on international regulations<br>
• Advise on post-market requirements
</td>
<td align="center">1</td>
</tr>
<tr>
<td><strong>Clinical Research Methodology</strong></td>
<td>
• Expertise in clinical trial design and biostatistics<br>
• Experience with medical device clinical studies<br>
• PhD in biostatistics, epidemiology, or related field<br>
• Publication record in clinical research methods<br>
• Experience with adaptive trial designs
</td>
<td>
• Design statistically rigorous clinical trials<br>
• Develop data analysis plans<br>
• Advise on sample size and power calculations<br>
• Guide interim analysis approaches<br>
• Support clinical evidence synthesis
</td>
<td align="center">1</td>
</tr>
</table>

### 4.2 Member Selection Criteria

Members will be selected based on the following criteria:

1. **Professional Qualifications**: Demonstrated expertise in relevant field with appropriate credentials
2. **Industry Recognition**: Standing as a key opinion leader or recognized expert
3. **Research Contributions**: Publication record and research impact in relevant areas
4. **Clinical Experience**: Direct experience with relevant patient populations or technologies
5. **Regulatory Knowledge**: Understanding of regulatory requirements for medical devices
6. **Collaborative Approach**: Demonstrated ability to work effectively in advisory roles
7. **Diversity Considerations**: Representation across gender, geography, and professional backgrounds
8. **Conflict Management**: Ability to manage potential conflicts of interest appropriately

### 4.3 Diversity and Inclusion

The CAB will prioritize diversity across multiple dimensions:

- **Gender Balance**: Minimum 40% representation of any gender
- **Geographic Diversity**: Representation from multiple regions to support global strategy
- **Institutional Diversity**: Members from academic, clinical, industry, and advocacy settings
- **Perspective Diversity**: Inclusion of varied viewpoints and approaches
- **Career Stage Diversity**: Mix of established leaders and emerging experts

## 5. Appointment and Terms

### 5.1 Selection Process

<div align="center">
<img src="https://mermaid.ink/img/pako:eNp1kk9PwzAMxb9KlBOI9QvkMG3qBBJiB8QOvUQmMY3WJlWSMjZV_e7YbVlhwJf4-fez_OzCuJUEBbwQb8lYvGvDLZIVUXxA8t5ZJA_WkVYRXdA6JGQvVkWUhLxGRWQMqQhXZJV3pCNcxHmcx1mcx_9i5_uoI1zGeZzHeZzH-b_YRYRXcR7ncR7ncR7nMXZ-jjrCdZzHeZzHeZzHeYyd36KO8C7O4zzO4zzO4zzGzh9RR_gY53Ee53Ee53EeY-fPqCP8ivM4j_M4j_M4j7HzLuoIf-I8zuM8zuM8zmPs_Bt1hMc4j_M4j_M4j_MYO0-ijvAU53Ee53Ee53EeY-c0wlOcx3mcx3mcx3mMnbMIT3Ee53Ee53Ee5zF2ziM8xXmcx3mcx3mcx9i5iPAU53Ee53Ee53EeY-cywnOcx3mcx3mcx3mMnasIz3Ee53Ee53Ee5zF2riO8xHmcx3mcx3mcx9i5ifAS53Ee53Ee53EeY-c2wkucx3mcx3mcx3mMnbsIL3Ee53Ee53Ee5zF27iO8xnmcx3mcx3mcx9h5iPAa53Ee53Ee53EeY-cxwmucx3mcx3mcx3mMnacIb3Ee53Ee53Ee5zF2niO8xXmcx3mcx3mcx9h5ifAW53Ee53Ee53EeY-c1wlucx3mcx3mcx3mMnbcI73Ee53Ee53Ee5zF23iO8x3mcx3mcx3mcx9j5iPAe53Ee53Ee53EeY-czwnucx3mcx3mcx3mMna8IH3Ee53Ee53Ee5zF2viN8xHmcx3mcx3mcx9j5ifAR53Ee53Ee53EeY-e_CB9xHudxHudxHucxdv4HxvXwKQ?type=png" alt="CAB Selection Process" width="600px" />
</div>

The selection process follows these steps:

1. **Nomination**: Candidates are nominated by Chimera leadership, existing CAB members, or through self-nomination with appropriate references
2. **Initial Screening**: Candidates are evaluated against selection criteria by the Clinical Affairs team
3. **Interview**: Qualified candidates undergo interviews with Chimera leadership and existing CAB members
4. **Reference Check**: Professional references and conflict of interest screening
5. **Selection Committee Review**: Final candidates reviewed by selection committee
6. **Board Approval**: Final appointments approved by Chimera Board of Directors
7. **Formal Invitation**: Official invitation extended to selected candidates

### 5.2 Term Length and Renewal

#### 5.2.1 Initial Terms
- Standard appointment is for a 2-year term
- Initial appointments will be staggered to ensure continuity:
  - 50% of initial members: 2-year terms
  - 50% of initial members: 1-year terms (renewable for a full 2-year term)

#### 5.2.2 Term Renewal
- Members may be renewed for one additional 2-year term
- Renewal is based on:
  - Attendance and participation record
  - Contributions to CAB objectives
  - Continued relevance of expertise
  - Mutual interest in continued service
- Maximum service is limited to 4 consecutive years
- After a 1-year hiatus, former members may be reconsidered

#### 5.2.3 Leadership Terms
- CAB Chair is elected by majority vote of members for a 2-year term
- Chair may serve a maximum of two consecutive terms
- Vice Chair position filled by Chair-elect during second year of Chair's term

### 5.3 Conflict of Interest Management

#### 5.3.1 Disclosure Requirements
- Members must disclose all potential conflicts of interest:
  - Upon initial appointment
  - Annually during service
  - When new conflicts arise
- Disclosures include:
  - Financial interests in competing technologies
  - Consulting relationships with competitors
  - Research funding from competing entities
  - Intellectual property related to BCI or exoskeleton technology

#### 5.3.2 Conflict Management
- Conflicts are reviewed by the Chimera Ethics Committee
- Management strategies include:
  - Recusal from specific discussions
  - Limitation on access to confidential information
  - Abstention from recommendations in conflict areas
  - Public disclosure of conflicts in publications
  - Resignation in cases of irreconcilable conflicts

#### 5.3.3 Confidentiality
- All CAB members must sign confidentiality agreements
- Discussions and materials shared with the CAB are considered confidential
- Confidentiality obligations extend 5 years beyond CAB service

## 6. Meetings and Operations

### 6.1 Meeting Frequency and Format

#### 6.1.1 Regular Meetings
- Quarterly full CAB meetings (minimum requirement)
- Two meetings per year must be in-person (when possible)
- Virtual meetings conducted via secure videoconference platform
- Additional subcommittee meetings as needed

#### 6.1.2 Special Meetings
- Emergency meetings may be called by:
  - CAB Chair
  - Chimera Chief Medical Officer
  - Request of majority of CAB members
- Special topic meetings for focused discussion on specific issues
- Regulatory milestone meetings aligned with submission timelines

#### 6.1.3 Annual Strategic Review
- Annual full-day in-person meeting
- Comprehensive review of clinical and regulatory strategy
- Long-term planning and priority setting
- Review of CAB effectiveness and charter updates

### 6.2 Meeting Procedures

#### 6.2.1 Preparation and Documentation
- Agenda and materials distributed at least 7 days before meetings
- Pre-reading materials provided for complex topics
- Standardized presentation templates for consistency
- Meeting minutes documented and distributed within 5 business days
- Action items tracked with assigned responsibilities and deadlines

#### 6.2.2 Attendance and Quorum
- Members expected to attend at least 75% of scheduled meetings
- Quorum requires attendance of at least 60% of members
- Remote participation accommodated when necessary
- Consistent non-attendance may result in membership review

#### 6.2.3 Meeting Structure
- Standard agenda includes:
  - Safety updates and discussion
  - Regulatory milestone review
  - Clinical study progress updates
  - Technical development updates
  - Discussion topics requiring CAB input
  - Action item review and assignment

### 6.3 Decision Making and Recommendations

#### 6.3.1 Consensus Approach
- Recommendations made by consensus whenever possible
- Structured discussion to identify areas of agreement
- Documentation of rationale for recommendations
- Consideration of alternative approaches

#### 6.3.2 Voting Procedures
- When consensus cannot be reached, formal voting is conducted
- Each member has one vote (Chair has tie-breaking vote)
- Simple majority required for recommendations
- Minority opinions documented in meeting minutes
- Abstentions recorded with rationale

#### 6.3.3 Recommendation Documentation
- Formal recommendations documented in standardized format
- Recommendations include:
  - Background and context
  - Options considered
  - Recommendation details
  - Implementation considerations
  - Dissenting opinions (if any)

### 6.4 Subcommittees and Working Groups

#### 6.4.1 Standing Subcommittees
- **Clinical Trial Subcommittee**: Focuses on study design and execution
- **Safety Monitoring Subcommittee**: Reviews safety data and risk management
- **Regulatory Strategy Subcommittee**: Guides regulatory submissions and interactions

#### 6.4.2 Ad Hoc Working Groups
- Temporary groups formed for specific issues
- Defined scope and deliverables
- Timeline for completion
- Reporting requirements to full CAB

#### 6.4.3 External Expert Consultation
- Process for engaging additional expertise when needed
- Temporary advisors for specialized topics
- Confidentiality requirements for external experts

## 7. Compensation and Support

### 7.1 Honoraria Structure

#### 7.1.1 Annual Retainer
- Base annual honorarium: $10,000-$15,000 per year
- Additional compensation for leadership roles:
  - Chair: Additional $5,000 annually
  - Subcommittee Chair: Additional $2,500 annually
- Prorated for partial year service

#### 7.1.2 Meeting Compensation
- In-person meeting attendance: $1,500-$2,500 per meeting
- Virtual meeting attendance: $750-$1,000 per meeting
- Subcommittee meeting attendance: $500-$750 per meeting
- Preparation time compensation: $250 per hour for significant pre-work

#### 7.1.3 Additional Activities
- Regulatory meeting participation: $2,500 per day
- Clinical site visits: $2,000 per day
- Document review: $300-$500 per hour
- Special projects: Negotiated based on scope

### 7.2 Expense Reimbursement

#### 7.2.1 Travel Expenses
- Business class airfare for flights over 4 hours
- Economy class for shorter flights
- Lodging at approved hotels
- Ground transportation
- Meals and incidentals per company policy

#### 7.2.2 Administrative Expenses
- Communication costs
- Printing and materials
- Software or tools required for CAB activities
- Administrative support for CAB-related work

#### 7.2.3 Reimbursement Process
- Standardized expense reporting system
- Submission deadline: 30 days after expense incurred
- Payment processing within 15 business days
- Direct deposit option available

### 7.3 Administrative Support

- Dedicated administrative coordinator for CAB activities
- Meeting scheduling and logistics coordination
- Documentation management and distribution
- Communication facilitation
- Expense processing and honoraria administration

## 8. Intellectual Property and Publications

### 8.1 Intellectual Property

#### 8.1.1 Ownership
- Intellectual property developed through CAB activities belongs to Chimera
- Members waive rights to royalties from IP developed during CAB service
- Pre-existing IP of members remains their property
- Improvements to pre-existing IP negotiated on case-by-case basis

#### 8.1.2 Recognition
- Members receive appropriate acknowledgment in patents
- Inventorship determined according to patent law
- Contribution to IP development documented

#### 8.1.3 Publication Rights
- Chimera maintains right of first publication for CAB-related work
- Members may publish with Chimera approval after initial publication
- Academic freedom respected within confidentiality constraints

### 8.2 Publication and Presentation

#### 8.2.1 Authorship
- Authorship follows ICMJE guidelines
- CAB members may serve as authors when criteria are met
- Acknowledgment of CAB contribution in publications
- Corporate authorship of CAB for certain publications

#### 8.2.2 Review Process
- CAB members may review publications prior to submission
- 15-day review period for manuscripts
- Focus on scientific accuracy and completeness
- Chimera maintains final editorial control

#### 8.2.3 Presentation Opportunities
- CAB members may present at conferences with approval
- Standard slides provided for consistency
- Recognition of CAB role in presentations
- Coordination of messaging across presenters

## 9. Current Advisory Board Members

<table>
<tr>
<th>Name</th>
<th>Institution</th>
<th>Expertise</th>
<th>Term</th>
</tr>
<tr>
<td>[TBD]</td>
<td>[TBD]</td>
<td>Neurology</td>
<td>2025-2027</td>
</tr>
<tr>
<td>[TBD]</td>
<td>[TBD]</td>
<td>Physical Medicine and Rehabilitation</td>
<td>2025-2027</td>
</tr>
<tr>
<td>[TBD]</td>
<td>[TBD]</td>
<td>Neuroscience</td>
<td>2025-2026</td>
</tr>
<tr>
<td>[TBD]</td>
<td>[TBD]</td>
<td>Bioethics</td>
<td>2025-2026</td>
</tr>
<tr>
<td>[TBD]</td>
<td>[TBD]</td>
<td>Patient Advocacy</td>
<td>2025-2027</td>
</tr>
<tr>
<td>[TBD]</td>
<td>[TBD]</td>
<td>Regulatory Affairs</td>
<td>2025-2026</td>
</tr>
<tr>
<td>[TBD]</td>
<td>[TBD]</td>
<td>Clinical Research Methodology</td>
<td>2025-2027</td>
</tr>
</table>

## 10. Reporting Structure and Governance

### 10.1 Reporting Relationships

<div align="center">
<img src="https://mermaid.ink/img/pako:eNp1kk9PwzAMxb9KlBOI9QvkMG3qBBJiB8QOvUQmMY3WJlWSMjZV_e7YbVlhwJf4-fez_OzCuJUEBbwQb8lYvGvDLZIVUXxA8t5ZJA_WkVYRXdA6JGQvVkWUhLxGRWQMqQhXZJV3pCNcxHmcx1mcx_9i5_uoI1zGeZzHeZzH-b_YRYRXcR7ncR7ncR7nMXZ-jjrCdZzHeZzHeZzHeYyd36KO8C7O4zzO4zzO4zzGzh9RR_gY53Ee53Ee53EeY-fPqCP8ivM4j_M4j_M4j7HzLuoIf-I8zuM8zuM8zmPs_Bt1hMc4j_M4j_M4j_MYO0-ijvAU53Ee53Ee53EeY-c0wlOcx3mcx3mcx3mMnbMIT3Ee53Ee53Ee5zF2ziM8xXmcx3mcx3mcx9i5iPAU53Ee53Ee53EeY-cywnOcx3mcx3mcx3mMnasIz3Ee53Ee53Ee5zF2riO8xHmcx3mcx3mcx9i5ifAS53Ee53Ee53EeY-c2wkucx3mcx3mcx3mMnbsIL3Ee53Ee53Ee5zF27iO8xnmcx3mcx3mcx9h5iPAa53Ee53Ee53EeY-cxwmucx3mcx3mcx3mMnacIb3Ee53Ee53Ee5zF2niO8xXmcx3mcx3mcx9h5ifAW53Ee53Ee53EeY-c1wlucx3mcx3mcx3mMnbcI73Ee53Ee53Ee5zF23iO8x3mcx3mcx3mcx9j5iPAe53Ee53Ee53EeY-czwnucx3mcx3mcx3mMna8IH3Ee53Ee53Ee5zF2viN8xHmcx3mcx3mcx9j5ifAR53Ee53Ee53EeY-e_CB9xHudxHudxHucxdv4HxvXwKQ?type=png" alt="Reporting Structure" width="700px" />
</div>

The CAB has the following reporting relationships:

- **Primary Reporting**: CAB Chair reports directly to the Chief Medical Officer
- **Executive Updates**: Quarterly updates to the Executive Leadership Team
- **Board Reporting**: Annual presentation to the Chimera Board of Directors
- **Regulatory Authority**: Recommendations provided to Regulatory Affairs team
- **Clinical Operations**: Guidance provided to Clinical Operations team
- **R&D Collaboration**: Input provided to R&D leadership

### 10.2 Accountability and Performance Metrics

#### 10.2.1 CAB Performance Metrics
- Meeting attendance and participation rates
- Timeliness of recommendations and deliverables
- Quality and impact of strategic guidance
- Contribution to regulatory milestones
- Support for clinical study enrollment and execution
- Publication and presentation contributions

#### 10.2.2 Individual Member Evaluation
- Annual performance review for each member
- Self-assessment component
- Peer evaluation component
- Chimera leadership evaluation
- Renewal decisions based on performance

#### 10.2.3 CAB Effectiveness Review
- Annual review of overall CAB effectiveness
- Assessment against strategic objectives
- Identification of improvement opportunities
- Benchmarking against industry best practices
- Charter updates based on effectiveness review

### 10.3 Amendment Process

This charter may be amended through the following process:

1. **Proposal**: Amendments may be proposed by CAB members, Chimera leadership, or Board of Directors
2. **Review**: Proposed amendments reviewed by CAB and Chimera legal counsel
3. **Approval**: Amendments require:
   - Two-thirds vote of CAB membership
   - Approval by Chimera Chief Medical Officer
   - Final approval by Chimera Board of Directors
4. **Implementation**: Approved amendments documented in updated charter version
5. **Distribution**: Revised charter distributed to all stakeholders

The charter will be reviewed annually to ensure alignment with industry best practices, regulatory requirements, and Chimera's evolving needs.

## 11. Conclusion

This Clinical Advisory Board Charter establishes a comprehensive framework for leveraging world-class expertise to guide the development, validation, and implementation of the Chimera brain-controlled exoskeleton platform. Through structured engagement with leading experts across relevant disciplines, Chimera will accelerate its path to market while ensuring the highest standards of safety, efficacy, and ethical implementation.

The CAB will play a critical role in navigating the complex regulatory landscape for novel neurotechnology, optimizing clinical validation strategies, and positioning Chimera for commercial success. By following the governance structure and operational procedures outlined in this charter, Chimera will maximize the value of expert insights while maintaining appropriate independence and scientific rigor.

This charter demonstrates Chimera's commitment to excellence in clinical and regulatory strategy, supporting our billion-dollar market potential through world-class advisory infrastructure.

---

<div align="center">
<p><em>This charter was established on April 16, 2025 and last updated on April 16, 2025.</em></p>

<p><strong>Document Control</strong></p>

| Version | Date | Author | Changes |
|---------|------|--------|---------|
| 2.0 | April 16, 2025 | Chimera Clinical Affairs | Enhanced version with comprehensive content and professional formatting |

<p><strong>Contact:</strong> <a href="mailto:clinical-advisory@chimera-bci.org">clinical-advisory@chimera-bci.org</a></p>

<p>
<img src="https://img.shields.io/badge/FDA-Compliance%20Ready-green?style=flat-square&logo=data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgMCAyNCAyNCI+PHBhdGggZD0iTTEyIDJDNi41IDIgMiA2LjUgMiAxMnM0LjUgMTAgMTAgMTAgMTAtNC41IDEwLTEwUzE3LjUgMiAxMiAyem0tMSAxNkg3di0yaDR2MnptNi40LTRINi42Yy0uOSAwLTEuNi0uNy0xLjYtMS42VjYuNkM1IDUuNyA1LjcgNSA2LjYgNWgxMC44Yy45IDAgMS42LjcgMS42IDEuNnY1LjhjMCAuOS0uNyAxLjYtMS42IDEuNnoiIGZpbGw9IndoaXRlIi8+PC9zdmc+" alt="FDA Compliance Ready">
<img src="https://img.shields.io/badge/ISO%2014155-Clinical%20Investigation-blue?style=flat-square" alt="ISO 14155 Compliant">
<img src="https://img.shields.io/badge/21%20CFR%20Part%2011-Compliant-blue?style=flat-square" alt="21 CFR Part 11 Compliant">
</p>

<p><em>This document is confidential and proprietary to Chimera. It may not be reproduced or distributed without permission.</em></p>
</div>
